Transarterial chemoembolization in Child-Pugh class B patients with hepatocellular carcinoma: Between the devil and the deep blue sea

Liver International

Volumn 30, Issue 6, 2010, Pages 923-924

  Giannini, Edoardo G ^a   Savarino, Vincenzo ^a   Risso, Domenico ^a   Nolfo, Maria Anna Di ^b   Poggio, Paolo Del ^c   Benvegnù, Luisa ^d   Farinati, Fabio ^d   Zoli, Marco ^e   Borzio, Franco ^f   Caturelli, Eugenio ^g   Chiaramonte, Maria ^h   Trevisani, Franco ^e  

^a UNIVERSITY OF GENOA   (Italy)

^b BOLOGNINI HOSPITAL   (Italy)

^c TREVIGLIO HOSPITAL   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f FATEBENEFRATELLI HOSPITAL   (Italy)

^g BELCOLLE HOSPITAL   (Italy)

^h SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SORAFENIB;

CHEMOEMBOLIZATION; HUMAN; INOPERABLE CANCER; KAPLAN MEIER METHOD; KIDNEY FAILURE; LETTER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PROGNOSIS; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; ITALY; LIVER NEOPLASMS; MORTALITY; PATHOLOGY; PATIENT SELECTION; RENAL INSUFFICIENCY; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; NEOPLASM STAGING; PATIENT SELECTION; RENAL INSUFFICIENCY; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 77954363522     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02220.x     Document Type: Letter

References (8)

1. Hsu CY, Huang YH, Su CW. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int 2010, 30:77-84.
2. Peck-Radosavljevic M. TACE it or leave it: hard choices for intermediate-stage hepatocellular carcinoma patients beyond perfect health. Liver Int 2010, 30:3-4.
3. Peck-Radosavljevic M, Greten TF, Lammer J. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol DOI, 10.1097/MEG.0b013e328333df23
4. Lo CM, Ngan H, Tso WK. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-71.
5. Llovet JM, Real MI, Montaña X. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised study. Lancet 2002, 359:1734-9.
6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-42.
7. Giannini EG, Bodini G, Corbo M. Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 2010, 31:493-501.
8. Mirici-Cappa F, Gramenzi A, Santi V. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20 year multicentre experience. Gut accepted for publication on 29 November 2009